This week we’ve seen financings and acquisitions news spanning the life sciences, IT, and cleantech sectors in New England.
—OpenMile, a Boston- and Chicago-based developer of Web and mobile technology for optimizing shipping, said it raised $6 million in a Series B deal led by Globespan Capital Partners, with participation from existing investor Charles River Ventures.
—Waltham, MA-based Bluespec, a maker of software for designing electronics components, grabbed $1 million in equity-based funding from four investors, an SEC filing showed. The company’s previous investors include Atlas Venture and North Bridge Venture Partners.
—DynamicOps, a Burlington, MA-based maker of software for cloud infrastructures and IT virtualization, snapped up an $11.3 million equity-based financing. The company was spun out of Credit Suisse in 2008.
—Marlborough, MA-based CardioFocus brought in $30.6 million to put toward its medical devices, which include a product for treating an irregular heart rhythm known as atrial fibrillation. The money comes from new investors First Alliance & Capital Invest, Fletcher Spaght Ventures, and Manatuck Hill Partners, as well as all of the startup’s previous investors.
—Boston non-profit Diagnostics For All nabbed a $3 million grant from the Bill & Melinda Gates Foundation and the UK’s Department for International Development to fund the creation of three new tests aimed at improving safety and productivity in agriculture. Diagnostics For All first spun out of Harvard to focus on diagnostic products in the human health space, and is led by veteran biotech executive Una Ryan.
—CHiL Semiconductor of Tewksbury, MA, said it is being acquired by Los Angeles-based power management firm International Rectifier (NYSE: IRF) in a $75 million cash deal expected to close before the end of this month. CHiL, which designs chips for power management in servers, PCs, and high-performance computing systems, has raised about $30 million since launching in 2006. International Rectifier, which has a manufacturing facility in Leominster, MA, said it will use the technology to help its customers focus on energy efficiency.
—Cambridge, MA-based NeuroPhage Pharmaceuticals, announced it had wrapped up $12.4 million in Series B financing led by Mérieux Développement. New investor Shire (NASDAQ: SHPGY), the Irish biopharma firm, also participated in the round for NeuroPhage, which is preparing its drug candidate for Alzheimer’s disease for Phase 1 clinical trials within the next two years.
–RXi Pharmaceuticals (NASDAQ: RXII), a Worcester, MA-based developer of RNA interference treatments, priced a public offering of common stock and warrants that is expected to gross $8.1 million. The proceeds of the offering, which is expected to close March 4, will be used for general corporate purposes.
—Cardiorobotics, a Raynham, MA-based developer of a robotic catheter for heart procedures, brought in $6.6 million out of an equity- and rights-based funding round that could total $12.5 million.
—Boston’s Sproxil, a company offering text message-based services for identifying counterfeit medication abroad, snapped up $1.8 million in funding from one investor, an SEC filing showed.
—Newton, MA-based Aircuity, a developer of a system for intelligently controlling air ventilation in commercial buildings, bumped up its most recent financing to $3.5 million out of a targeted $10 million equity round, an SEC filing showed. The firm reported last year that it raised $2.5 million from six investors; the new cash comes from one additional investor, according to the federal documents.
By posting a comment, you agree to our terms and conditions.